- Home
- ADAG vs ANEB Comparison
ADAG vs ANEB Comparison
Compare ADAG & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAG | ANEB |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 96.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ADAG | ANEB |
|---|---|---|
| Price | $1.93 | $1.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 73.7K | ★ 100.2K |
| Earning Date | 08-12-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $103,204.00 | N/A |
| Revenue This Year | $6,983.06 | N/A |
| Revenue Next Year | $36.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $0.90 |
| 52 Week High | $3.16 | $3.42 |
Technical Indicators
Market Signals| Indicator | ADAG | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 19.23 |
| Support Level | $1.76 | $1.91 |
| Resistance Level | $1.90 | $2.40 |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 53.19 | 3.97 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.